Matthew H. Kulke, MD

Articles by Matthew H. Kulke, MD

Dr. Kulke on Emerging Cabozantinib Data for NETs

February 1st 2018

Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).

Latest Updated Articles

Dr. Kulke on Emerging Cabozantinib Data for NETs
Published: February 1st 2018 | Updated:

Matthew H. Kulke, MD

Articles by Matthew H. Kulke, MD

Dr. Kulke on Emerging Cabozantinib Data for NETs

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care